Eli Lilly (LLY) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $1.08T | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | US | CEO | David A. Ricks |
| IPO Date | 1972-06-01 | CAGR | 7.77% |
| Employees | 50,000 | Website | www.lilly.com |
| Div. Yield | 1.23% | Payout Ratio | 22.1% |
| Buy Back Yield | 1.04% | Total Yield | 2.27% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $939.46B | P/E | 39.04 | Forward P/E | 25.5 | PEG | 0.24 |
| P/S | 8.18 | P/B | 18.03 | P/CF | 27.46 | P/FCF | 43.61 |
| Sales | $72.25B | Sales 1Y | 47.44% | Sales 3Y | 160.91% | Sales 5Y | 183.49% |
| EPS | $29.42 | EPS 1Y | 129.05% | EPS 3Y | 359.97% | EPS 5Y | 342.61% |
| Sales QoQ | 2.63% | EPS QoQ | 11.77% | Sales QoQ Avg | 11.9% | EPS QoQ Avg | 33.76% |
| Gross Margin | 83.51% | Operating Margin | 45.87% | Profit Margin | 34.98% | ROCE | 41.45% |
| ROA | 22% | ROE | 101% | Altman Z Score | 9.65 | Piotroski Score | 6 |
| Current Ratio | 1.5 | Quick Ratio | 1.1 | Cash Ratio | 0.14 | Op. CF Ratio | 0.15 |
| Debt/Equity | 1.39 | Debt/Assets | 0.37 | Lt Debt/Equity | 1.26 | Lt Debt/Cap. | 0.56 |
| Intrst Cov. | 37.5 | Inventory Turnover | 0.82 | Asset Turnover | 0.62 | Receivables Turnover | 3.41 |
| Enterprise Value | $939.46B | P/E Ratio | 39.04 |
| Forward P/E | 25.5 | PEG Ratio | 0.24 |
| P/S Ratio | 8.18 | P/B Ratio | 18.03 |
| P/CF Ratio | 27.46 | P/FCF Ratio | 43.61 |
| EPS | $29.42 | EPS Growth 1Y | 129.05% |
| EPS Growth 3Y | 359.97% | EPS Growth 5Y | 342.61% |
| Revenue Growth 1Y | 47.44% | Gross Margin | 0.84% |
| Operating Margin | 0.46% | Profit Margin | 0.35% |
| ROE | 1.01% | ROA | 0.22% |
| ROCE | 0.41% | Current Ratio | 1.5 |
| Quick Ratio | 1.1 | Cash Ratio | 0.14 |
| Debt/Equity | 1.39 | Interest Coverage | 37.5 |
| Altman Z Score | 9.65 | Piotroski Score | 6 |
Eli Lilly (LLY) valuation & financials
Eli Lilly (LLY) has a market capitalization of $1.08T and trades at a price-to-earnings ratio of 39.0. It operates in the Healthcare sector (Drug Manufacturers - General).
Eli Lilly's revenue grew +47.4% over the last year.
Eli Lilly's next earnings report is scheduled for August 5, 2026 before market open; analysts estimate EPS of $7.47.
Eli Lilly (LLY) — frequently asked questions
When does Eli Lilly (LLY) report earnings next?
Eli Lilly is expected to report earnings on August 5, 2026 before market open. Analysts estimate EPS of $7.47.
What is Eli Lilly's market cap?
Eli Lilly (LLY) has a market capitalization of $1.08T.
What is LLY's P/E ratio?
Eli Lilly trades at a price-to-earnings ratio of 39.0, with trailing twelve-month EPS of $29.42.
How fast is Eli Lilly growing?
Eli Lilly's revenue grew +47.4% over the last year.
Compare with other Healthcare companies: Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW) · Novartis (NVS)